Conclusions-These data support the value of long term use of D blockers in patients at risk of myocardial infarction. They suggest that patients taking these agents before admission to hospital with myocardial infarction have a significant survival advantage at 28 days, which may be due to a reduction in infarct size.
Introduction
Though patients taking an oral [3 blocker after acute myocardial infarction have a reduced risk of sudden out of hospital cardiac death and reinfarction,' it is not known whether these patients continue to derive benefit from this treatment after admission to hospital with myocardial infarction. This study therefore compared morbidity and mortality at 28 days after myocardial infarction in patients who were and were not taking an oral (3 blocker at the time of admission.
Detection of a measurable effect of 13 blockers on 28 day survival in these patients would have important implications regarding their long term use in patients at risk of myocardial infarction and also would help show whether the widespread use of these agents in the community has contributed to the decline in mortality at 28 days after myocardial infarction.
Patients and methods
We studied data from patients aged 25-64 living within the Perth statistical division who were admitted to hospital with a myocardial infarction during the four years 1984-7. The data form a subset of those collected as part of the MONICA project, an international study conducted (975) of those in the non-(3 blocker group had started (3 blockers. Table I compares the clinical details of patients who were and were not taking a ( blocker at the time of admission. Patients in the (3 blocker group were older, more likely to be women, and more likely to have a past history of acute myocardial infarction, angina, hypertension, and coronary artery bypass surgery. They were also more likely to be non-smokers and to be receiving other forms of treatment, including calcium channel blockers, diuretics, and nitrates. The maximum pulse rate recorded in the first 24 hours after admission was lower in patients taking a (3 blocker (p<O 001) but blood pressure on admission was higher.
The frequency of left ventricular failure and the proportion of patients with anterior infarction were almost identical in the two groups. When the prior use of a (3 blocker was added to the model it was found to be associated with an independent beneficial effect on mortality (relative risk 0 50; 95% confidence interval 0 34 to 0 76), which was most evident in patients surviving the first 24 hours after admission (relative risk 0 31; 95% confidence interval 0 18 to 0 54) (table IV). The expected overall mortality among the patients at 28 days had no patient been taking a (3 blocker was 14-6% (354 deaths) as opposed to the observed figure of 13-4% (325 deaths). Table V lists the complications affecting the two groups of patients. The incidence of atrial fibrillation was similar in each group and complete heart block tended to be more frequent (p=0 055) in the i3 blocker group. Though ventricular tachycardia (three or more consecutive ventricular beats) was less common in the c blocker group (p=0004), the overall incidence of ventricular fibrillation was higher in these patients (p<OOOl). Pulmonary oedema was more frequent in the 3 blocker group but there was no significant difference in the incidence of cardiogenic shock between the groups. Peak creatine kinase activities in patients surviving the first 24 hours of admission were lower among those taking a 0 blocker (p=OOOl; Wilcoxon rank test) (table I).
Discussion
Treatment with t3 blockers given intravenously during the early hours after acute myocardial infarction has been shown to reduce early cardiac mortality,9 possibly by reducing infarct size.'0 Furthermore, when given to patients surviving myocardial infarction oral I3 blockers reduce the incidence of both out of hospital sudden cardiac death and recurrent myocardial infarction.' "-" In this study we tested the hypothesis that patients taking a j3 blocker at the time of onset of acute myocardial infarction would receive a benefit from this treatment and that this would be detectable as a reduction in mortality at 28 days after the acute event.
In this community based study 574 (24%) of 2430 patients admitted to hospital with acute myocardial infarction were taking a 1 blocker. This high proportion reflects the high prevalence of hypertension and angina among patients developing myocardial infarction and also highlights the widespread use of ,B blockers in this community.' Though these patients were at high risk of early cardiac death by virtue of being older and having a higher prevalence of past angina, myocardial infarction, hypertension, or bypass surgery, 28 day mortality was similar to that of patients who were not taking a 3 blocker at the time of infarction. After correction for these and other recognised adverse influences on survival it was confirmed that patients taking a (3 blocker before the onset of myocardial infarction had a significantly reduced risk of death at 28 days, their overall relative risk being 0 50.
A possible interpretation of these data is that patients taking a 13 blocker at the time of myocardial infarction were more likely to die suddenly before they could be admitted to after myocardial infarction. Taken together, these results are consistent with the hypothesis that the efficacy of (3 blockers in myocardial infarction is dependent on when they are given.
In conclusion, this community based study suggests that prior treatment with oral (3 blockers may confer a "cardioprotective effect" in patients admitted to hospital with acute myocardial infarction. Though this benefit does not seem to be due to a reduction in serious arrhythmias, it may be due to a reduction in infarct size. An important consequence of these data is that they support the long term use of (3 blockers in patients at risk of myocardial infarction. They also suggest that the widespread use of ( blockers in the community has contributed to the decline in 28 day mortality of patients admitted to hospital with myocardial infarction.
We thank Nicholas de Klerk and Richard Hockey for constructive criticisms of early drafts of this paper. 
